{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:45:37Z","timestamp":1787507137361,"version":"build-2736575974"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jgo.2023.101631","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T07:43:04Z","timestamp":1696059784000},"page":"101631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["New treatment opportunities for older patients with acute myeloid leukemia and the increasing importance of frailty assessment \u2013 An oncogeriatric perspective"],"prefix":"10.1016","volume":"15","author":[{"given":"Benno","family":"Diekmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolijn","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Hempenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"van Roon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Franken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mels","family":"Hoogendoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2023.101631_bb0005","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.jgo.2023.101631_bb0010","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1007\/s00277-021-04631-8","article-title":"Long-term trends in the clinical outcomes of patients with acute myeloid leukemia: a population-based real-world data analysis using the Osaka Cancer Registry","volume":"100","author":"Fuji","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jgo.2023.101631_bb0015","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1186\/s12885-015-1857-x","article-title":"The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study","volume":"15","author":"Mohammadi","year":"2015","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.jgo.2023.101631_bb0020","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.jgo.2023.101631_bb0025","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.jgo.2023.101631_bb0030","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jgo.2023.101631_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.2046","article-title":"Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?","volume":"32","author":"Ferrara","year":"2014","journal-title":"Hematol Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2023.101631_bb0040","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1634\/theoncologist.2008-0224","article-title":"Acute myelogenous leukemia in older adults","volume":"14","author":"Klepin","year":"2009","journal-title":"Oncologist."},{"issue":"3","key":"10.1016\/j.jgo.2023.101631_bb0045","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.jgo.2023.101631_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020415","article-title":"Azacitidine for front-line therapy of patients with AML: reproducible efficacy established by direct comparison of international phase 3 trial data with registry data from the austrian azacitidine registry of the AGMT Study Group","volume":"18","author":"Pleyer","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"21","key":"10.1016\/j.jgo.2023.101631_bb0055","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jgo.2023.101631_bb0060","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jgo.2023.101631_bb0065","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jgo.2023.101631_bb0070","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.jgo.2023.101631_bb0075","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jgo.2023.101631_bb0080","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe francophone des myelodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.jgo.2023.101631_bb0085","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jgo.2023.101631_bb0090","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.jgo.2023.101631_bb0095","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00277-021-04465-4","article-title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial","volume":"100","author":"Heuser","year":"2021","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jgo.2023.101631_bb0100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia."},{"issue":"7","key":"10.1016\/j.jgo.2023.101631_bb0105","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"Sekeres","year":"2021","journal-title":"Leukemia."},{"issue":"17","key":"10.1016\/j.jgo.2023.101631_bb0110","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ades","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jgo.2023.101631_bb0115","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/ijc.30186","article-title":"Survival in patients with acute myeloblastic leukemia in Germany and the United States: major differences in survival in young adults","volume":"139","author":"Pulte","year":"2016","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2023.101631_bb0120","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/cam4.2740","article-title":"The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jgo.2023.101631_bb0125","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/16078454.2020.1843752","article-title":"The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2020","journal-title":"Hematology."},{"issue":"16","key":"10.1016\/j.jgo.2023.101631_bb0130","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jgo.2023.101631_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jgo.2023.101631_bb0140","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2012.067892","article-title":"Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome","volume":"98","author":"Deschler","year":"2013","journal-title":"Haematologica."},{"issue":"11","key":"10.1016\/j.jgo.2023.101631_bb0145","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2021013671","article-title":"Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML","volume":"139","author":"Min","year":"2022","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.jgo.2023.101631_bb0150","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jgo.2023.101631_bb0155","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.jgo.2023.101631_bb0160","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/EDBK_239097","article-title":"More versus less therapy for older adults with acute myeloid leukemia: new perspectives on an old debate","volume":"39","author":"Klepin","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"24","key":"10.1016\/j.jgo.2023.101631_bb0170","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood."},{"issue":"17","key":"10.1016\/j.jgo.2023.101631_bb0175","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.jgo.2023.101631_bb0180","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/bloodadvances.2020002846","article-title":"Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS","volume":"4","author":"Huls","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jgo.2023.101631_bb0185","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.jgo.2023.101631_bb0200","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/leu.2013.176","article-title":"Declining rates of treatment-related mortality in patients with newly diagnosed AML given \u2018intense\u2019 induction regimens: a report from SWOG and MD Anderson","volume":"28","author":"Othus","year":"2014","journal-title":"Leukemia."},{"issue":"15","key":"10.1016\/j.jgo.2023.101631_bb0205","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2023.101631_bb0210","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1200\/JCO.2008.18.2006","article-title":"Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in Sweden","volume":"27","author":"Kristinsson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.jgo.2023.101631_bb0215","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"Winters","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jgo.2023.101631_bb0220","first-page":"421","article-title":"Leukemia: new perspectives on an old debate","volume":"39","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"10.1016\/j.jgo.2023.101631_bb0230","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.jgo.2023.101631_bb0235","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.jgo.2023.101631_bb0240","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/OTT.S336715","article-title":"Rapid and efficient response to gilteritinib and venetoclax-based therapy in two AML patients with FLT3-ITD mutation unresponsive to venetoclax plus azacitidine","volume":"15","author":"Zhang","year":"2022","journal-title":"Onco Targets Ther"},{"issue":"24","key":"10.1016\/j.jgo.2023.101631_bb0245","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.jgo.2023.101631_bb0250","doi-asserted-by":"crossref","first-page":"701690","DOI":"10.3389\/fphar.2021.701690","article-title":"Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network Meta-analysis","volume":"12","author":"Ma","year":"2021","journal-title":"Front Pharmacol"},{"issue":"S1","key":"10.1016\/j.jgo.2023.101631_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5045\/br.2022.2021218","article-title":"Assessing frailty using comprehensive geriatric assessment in older patients with hematologic malignancy","volume":"57","author":"Choi","year":"2022","journal-title":"Blood Res"},{"issue":"3","key":"10.1016\/j.jgo.2023.101631_bb0260","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11899-018-0454-x","article-title":"Frailty in hematologic malignancy","volume":"13","author":"Koll","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jgo.2023.101631_bb0265","article-title":"Prevalence of prefrailty and frailty among older adults in germany: a systematic review, meta-analysis and meta-regression","volume":"9","author":"Hajek","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.jgo.2023.101631_bb0270","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19063669","article-title":"Frailty among older people during the first wave of the COVID-19 pandemic in the Netherlands","volume":"19","author":"Sealy","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"10.1016\/j.jgo.2023.101631_bb0275","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","article-title":"Geriatric assessment in older patients with a hematologic malignancy: a systematic review","volume":"105","author":"Scheepers","year":"2020","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.jgo.2023.101631_bb0280","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy \u2013 a systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.jgo.2023.101631_bb0285","doi-asserted-by":"crossref","first-page":"775050","DOI":"10.3389\/fonc.2021.775050","article-title":"Integration of a geriatric assessment with intervention in the care of older adults with hematologic malignancies","volume":"11","author":"Wall","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2023.101631_bb0290","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/10428194.2023.2165394","article-title":"Comorbidity burden and outcomes of older adults with acute promyelocytic leukemia: a National Cancer Database analysis of 2221 patients","volume":"64","author":"Dhakal","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.jgo.2023.101631_bb0295","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.jgo.2023.101631_bb0300","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood.2020005498","article-title":"Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia","volume":"136","author":"Saad","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.jgo.2023.101631_bb0305","series-title":"Hemato-oncologische zorg in Nederland","author":"IKNL","year":"2021"},{"key":"10.1016\/j.jgo.2023.101631_bb0310","first-page":"1","article-title":"Acute myeloid leukemia in the older adults","volume":"6","author":"Almeida","year":"2016","journal-title":"Leuk Res Rep"},{"issue":"5","key":"10.1016\/j.jgo.2023.101631_bb0315","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.jgo.2023.101631_bb0320","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/gerona\/glt039","article-title":"Performance status in elderly patients with acute myeloid leukemia: exploring gene expression signatures of cytokines and chemokines","volume":"70","author":"Nipp","year":"2015","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"5","key":"10.1016\/j.jgo.2023.101631_bb0325","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2141.2009.07663.x","article-title":"Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials","volume":"145","author":"Wheatley","year":"2009","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.jgo.2023.101631_bb0330","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.jgo.2023.101631_bb0335","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2023.101631_bb0340","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jgo.2020.05.011","article-title":"Clinical judgment versus geriatric assessment for frailty in older patients with cancer","volume":"11","author":"van Walree","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2023.101631_bb0345","article-title":"Frailty in patients with acute myeloid leukaemia, conceptual misapprehension of chronological age","volume":"27","author":"Umit","year":"2018","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"3","key":"10.1016\/j.jgo.2023.101631_bb0350","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1040-8428(00)00090-1","article-title":"Measurement and impact of comorbidity in older cancer patients","volume":"35","author":"Extermann","year":"2000","journal-title":"Crit Rev Oncol Hematol"},{"issue":"22","key":"10.1016\/j.jgo.2023.101631_bb0355","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2023.101631_bb0360","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.critrevonc.2005.06.003","article-title":"Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG)","volume":"55","author":"Extermann","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.jgo.2023.101631_bb0365","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11912-017-0631-4","article-title":"Using Geriatric Assessment Strategies to Lead End-of-Life Care Discussions","volume":"19","author":"Baronner","year":"2017","journal-title":"Curr. Oncol Rep."},{"issue":"19","key":"10.1016\/j.jgo.2023.101631_bb0370","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1200\/JCO.21.00242","article-title":"Advances in management for older adults with hematologic malignancies","volume":"39","author":"Rosko","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2023.101631_bb0375","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.jgo.2023.101631_bb0380","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1200\/JCO.2017.72.8170","article-title":"Time to stop saying geriatric assessment is too time consuming","volume":"35","author":"Hamaker","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jgo.2023.101631_bb0385","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/(SICI)1099-1166(199911)14:11<936::AID-GPS39>3.0.CO;2-1","article-title":"Validation of a 6 item cognitive impairment test with a view to primary care usage","volume":"14","author":"Brooke","year":"1999","journal-title":"Int J Geriatr Psychiatry"},{"issue":"8","key":"10.1016\/j.jgo.2023.101631_bb0390","first-page":"314","article-title":"The modified mini-mental state (3MS) examination","volume":"48","author":"Teng","year":"1987","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.jgo.2023.101631_bb0395","doi-asserted-by":"crossref","first-page":"M85","DOI":"10.1093\/geronj\/49.2.M85","article-title":"A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission","volume":"49","author":"Guralnik","year":"1994","journal-title":"J Gerontol"},{"issue":"4","key":"10.1016\/j.jgo.2023.101631_bb0400","first-page":"709","article-title":"Geriatric depression scale","volume":"24","author":"Yesavage","year":"1988","journal-title":"Psychopharmacol Bull"},{"issue":"1","key":"10.1016\/j.jgo.2023.101631_bb0405","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clnu.2004.07.015","article-title":"Development and validation of a hospital screening tool for malnutrition: the short nutritional assessment questionnaire (SNAQ)","volume":"24","author":"Kruizenga","year":"2005","journal-title":"Clin Nutr"},{"issue":"1 Pt 2","key":"10.1016\/j.jgo.2023.101631_bb0410","first-page":"S59","article-title":"Assessing the nutritional status of the elderly: the mini nutritional assessment as part of the geriatric evaluation","volume":"54","author":"Guigoz","year":"1996","journal-title":"Nutr Rev"},{"issue":"5 Suppl","key":"10.1016\/j.jgo.2023.101631_bb0415","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00005650-197605001-00018","article-title":"12. Index of ADL","volume":"14","author":"Katz","year":"1976","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.jgo.2023.101631_bb0420","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist."},{"issue":"5","key":"10.1016\/j.jgo.2023.101631_bb0425","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/geront\/41.5.652","article-title":"The zarit burden interview: a new short version and screening version","volume":"41","author":"Bedard","year":"2001","journal-title":"Gerontologist."},{"issue":"11","key":"10.1016\/j.jgo.2023.101631_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(21)00241-6","article-title":"A comprehensive approach to therapy of haematological malignancies in older patients","volume":"8","author":"Cordoba","year":"2021","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.jgo.2023.101631_bb0435","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/ajh.24087","article-title":"A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy","volume":"90","author":"Griffin","year":"2015","journal-title":"Am J Hematol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940682300228X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940682300228X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:59:42Z","timestamp":1761818382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187940682300228X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S187940682300228X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2023.101631","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatment opportunities for older patients with acute myeloid leukemia and the increasing importance of frailty assessment \u2013 An oncogeriatric perspective","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2023.101631","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101631"}}